ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Membranous nephropathy

Ronco, Pierre*; Beck, Laurence; Debiec, Hanna; Fervenza, Fernando C.; Hou, Fan Fan; Jha, Vivekanand; Sethi, Sanjeev; Tong, Allison; Vivarelli, Marina; Wetzels, Jack南方医科大学
Nature Reviews Disease Primers2021-9-30DOI: 10.1038/s41572-021-00303-z
135被引9阅读
引用收藏
分享

摘要

Membranous nephropathy (MN) is a glomerular disease that can occur at all ages. In adults, it is the most frequent cause of nephrotic syndrome. In similar to 80% of patients, there is no underlying cause of MN (primary MN) and the remaining cases are associated with medications or other diseases such as systemic lupus erythematosus, hepatitis virus infection or malignancies. MN is an autoimmune disease characterized by a thickening of the glomerular capillary walls due to immune complex deposition. Identification of the phospholipase A2 receptor (PLA2R) as the major antigen in adults in 2009 induced a paradigm shift in disease diagnosis and monitoring and several other antigens have since been characterized. Disease outcome is difficult to predict and around one-third of patients will undergo spontaneous remission. In those at high risk of progression, immunosuppressive therapy with cyclophosphamide plus corticosteroids has substantially reduced the need for kidney replacement therapy. Owing to carcinogenic risk, other treatments (calcineurin inhibitors and CD20-targeted B cell depletion therapy (rituximab)) have been developed. However, disease relapses are frequent when calcineurin inhibitors are stopped and the remission rate with rituximab is lower than with cyclophosphamide, particularly in patients with high PLA2R antibody titres. Other new drugs are already available and antigen-specific immunotherapies are being developed.

学科与关键词

关键词
PHOSPHOLIPASE A(2) RECEPTORDOMAIN-CONTAINING 7ASYSTEMIC-LUPUS-ERYTHEMATOSUSNEPHROTIC SYNDROMEANTI-PLA2R ANTIBODIESPLA2R AUTOANTIBODIESGLOMERULAR-DISEASESPROTEOMIC ANALYSISKIDNEY-DISEASEEXPERIMENTAL GLOMERULONEPHRITIS
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
Nature Reviews Disease Primers
发表日期
2021-09-30
卷期
第 7 卷, 第 1 期
页码
69
DOI
10.1038/s41572-021-00303-z
期刊收录
NSL
期刊等级
1区
成果收录
SCIE
资助标注
Dutch Kidney Foundation [NSN 17PhD12]; European Union [305608]; Baxter Healthcare; GSK; NephroPlus; National Research Agency: MNaims [ANR-17-CE17-0012-01]; National Research Agency: SeroNegMN [ANR-20-CE17-0017-01]; Genentech Inc.; Roche; MorphoSys; National Health and Medical Research Council Investigator Award [1197324]; Clinical Innovation Research Program of Guangzhou Regenerative Medicine and Health Guangdong Laboratory [2018GZR0201003]; National Health and Medical Research Council of Australia [1197324] Funding Source: NHMRC

作者

  • R

    Ronco, Pierre (通讯) (第一作者)

  • B

    Beck, Laurence

查看全部 10 位作者收起作者
  • D

    Debiec, Hanna

  • F

    Fervenza, Fernando C.

  • H

    Hou, Fan Fan

    southern med univ

  • J

    Jha, Vivekanand

    new

  • S

    Sethi, Sanjeev

  • T

    Tong, Allison

  • V

    Vivarelli, Marina

  • W

    Wetzels, Jack

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417